Drug intelligence / Profile preview

IMC-2011

Development stage: Unknown
Lead developer: ImmuneCyte Life Sciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

IMC-2011 is an autologous stem cell therapy candidate being developed by ImmuneCyte Life Sciences for the treatment of Critical Limb Ischemia (CLI). The therapy is produced using the company's proprietary AutoSTEM platform, which is an automated, closed-system manufacturing process designed to generate high-quality, standardized stem cell products. IMC-2011 aims to restore blood flow and promote tissue repair in patients with severe peripheral artery disease by stimulating angiogenesis and reducing inflammation in the affected limbs. The AutoSTEM platform is intended to overcome the scalability and consistency challenges typically associated with manual cell therapy production.

Beyond the preview

Go deeper on IMC-2011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC-2011.

Explore the full profile